Blue Earth, UCL Treat First Patient with Ac-225 PSMA Targeted Alpha Therapy

First patient dosed with Ac-225 PSMA-targeted alpha therapy in a clinical trial by Blue Earth and UCL, evaluating safety and efficacy for prostate cancer.

• The milestone marks the start of clinical evaluation for this targeted radioligand therapy.
• The trial is being conducted by Blue Earth and University College London; no efficacy or safety data have been released yet.

RadPigeon summaries are original and for information only. They are not clinical advice.